A Rollover Study of NBM-BMX in Combination With Temozolomide in Patients With Newly Diagnosed Glioblastoma

This clinical trial is a rollover study designed to provide continued access to NBM-BMX and temozolomide (TMZ) for eligible participants with newly diagnosed glioblastoma who have completed the designated treatment in Study NBM-BMX-003 (the parent study), and to evaluate the long-term safety and efficacy of NBM-BMX administered in combination with TMZ.

Trial Details

NCT ID
NCT07569042
Phase
PHASE1 / PHASE2
Sponsor
Novelwise Pharmaceutical Corporation
Status
RECRUITING
Cancer Type
Glioblastoma (GBM) Brain Cancer
Interventions
  • NBM-BMX Capsule
  • Temozolomide
Locations (sample)
  • Kaohsiung City, Taiwan|22.61626,120.31333
  • Taichung, Taiwan|24.1469,120.6839
  • Taoyuan City, Taiwan|24.99368,121.29696

Key Eligibility Criteria

  • Participants must meet all of the following criteria to be eligible for the study:
  • Have completed or currently enrolled in Arm B of Study NBM-BMX-003 (the parent study), and in the opinion of the Investigator, may derive clinical …
  • Histologically confirmed glioblastoma.
  • Can enroll into this rollover study within 35 days after completing the last dose of NBM-BMX in the parent study.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Glioblastoma (GBM) Brain Cancer Trials on Trialify →